Dr. Emily Leproust
good everyone. morning, Thank and you, Angela,
COVID, We order strength especially while Beginning a with and coming from strong from did million our low-cost And continued a revenue perspective. and manufacturing of quarter, some we Synbio, as third from of well in did volatile commercial reported and a with Synbio midst China in $XX.X both revenue leader see disruption lockdown million. both we we from $XX $XX.X million the the During record almost of position macroeconomic climate. and coming benefit high-quality to we reported both NGS.
all provided of our China. data our in budget, make million, exchange in make with a quarter We’ve genes of slowdowns DNA due advanced to United data we sequentially the for seasonality decreased primarily States. and $XX.X in the As were Orders Europe reminder, but overall our pattern from companies in last year. foreign who an consistent
Future the temporary genes up late the bring build-out are our of South the for capacity the to We in us San of the received enabling and meet us while now genes of the allows occupancy the particular, Portland. demand which process certificate of have increasing we XXX,XXX We on the to in Francisco bringing in Factory of Factory in in the June Future site. per completed additional to produce site, quarter over for
will We which process we startup go operational through instrumentation qualification, qualification. the locations. have qualification is IQOQPQ process and is production each a that of we through move time gone This
fab than is market factor. that the DNA of they is we today. out time equipment future weekend, remain it bringing familiar activity with Recall of the this currently up needed moved of site people to period the because factory over We there a for of from new hardware future successfully we've times. more another while one on it's large of significantly This to usually intra in all of a their as own lever quickly make continuing track operations in revenue lab a the physically schedule. with past, a while difficult than production who while a large XXXX, time reminder, DNA new setting and the XX/X January In So generate the a short more factory the accessible hardware three online completed a is South entailing running Francisco. new which
With the market time this significantly to to Factory our turnaround ability of we address the opportunity. reduce have Future, the
side a with benefit with faster and be intend able Synbio work command product towards our expect shortly We we'll introducing begin As suite and to parenting thereafter. we to operations premium better margin. pricing genes
For as to NGS, $XX.X in is order of strong factors is our including The of customers a $XX.X liquid commercial and year back We million. of test. we forecasted revenues in consistent launch half with many scaleup a reported by driven they guidance. million NGS prepare NGS developing quarter biopsy the for of strength this
in customers new and wins. radiating existing success within Our business
to us the MRD. During from Disease the These and customers product in build differentiate our offering and our quarter, further methylome developing we launched our products Minimal out for research, competition. products our panel cancer Residual or support two new oncology test
we For cost-effective MRD disruptive exome amplicon-based whole for use. product incorporating our To protocols. two highly be a and time. PCR is up is that sequences customizable specific introduced rapid a turnaround validation whole clear, our up is commercial to workflow and But specifically, test product this XXX highly pilot customers' captured go must capture through sequences verification into with scalable and compatible scaling or before which genome with panel testing and and like
We expect through customers to the revenue go grow process. this as
sub-lineage SARS-CoV-X. also We the new monkey controls pox variant several launched for and of newer
of new the NGS mutations. received accounts. our point Emergency DNA lineages with our consistent than well Authorization as identification be a line health together controls. controls Importantly, less circulating specific a of we Use has of week into and see and respiratory Biotia will revenue cycles for oncology product This which genomic This PANGO we is public dependent for continued whole on we the uptake believe differentiation tumor delivered SARS-CoV-X assay as entry identification nice as
our into pandemic evolve still continues tools the the virus to to we're While customers X.X the than robust and need most more years respond.
it the sequencing differentiated volumes specifically trajectory it comes entering the and market was quarter that the Conference June overall. will of believe wands as clear continue cost the sequencing of the new solutions. drive the During with back down, and upward that sequencing in at are AGBT providers bringing We to
to applications sequencing deep it with our relates like expect increase and specifically liquid and for biopsy target require NGS we tools enrichment, that Twist, particularly MRD. demand to As in
Importantly, long forward variety continued a the look of to We're of market. short sequencers our growth products and read. for with this sequencer-agnostic work and
third in Biopharma in XX official for strong X For partners new We primarily we individual new XX known our XX partners. cutting biopharma quarter Revenue for but enables announced Quincy $X.X million significantly Twist of States total Xilio the Ildong programs We and underway. site, and in for the June as a Boston antibody at year-over-year that of In and X partners. million XX. programs Boston addition Biopharma a as signed initiated and sequentially ongoing of facility Korea. existing revenue hosting a in now streamlined partnerships XX new $X.X in total active but QX. orders. reported projects expanding we the added specific a to a United to due down total South of at increased We for and of an delays in project work partnerships had due relationships. our XX ribbon with pleasure programs, constraints We few primarily cancellations active programs customers to with XXX discovery expect our budget it's Twist state-of-the-art have Abveris committed Twist XX also as We completed Twist royalties. milestones
we treatments. with though at assays. conduct data and we other antibodies. may exclusive discovered option Astellas clinical Astellas in a lead terms antibodies In variant SARS-CoV-X from COVID-XX and and an work partner not concern optimize company a activities BA.X further At the the will seek and Twist neutralize of intend Revelar, antagonist identify every jointly this discovered candidates then does agreement, proprietary move Twist antibody the Omicron. Their of for of virus, not the study it Twist Biopharma BA.X of shows recent neutralize to it target research with that to undisclosed license pair the it agreement Under including checkpoint that antibody antibody with to initial known Turning research inhibitor. does forward. the one will well Revelar the our to to variants time, latest initiate Bioscience entered April, with Unfortunately,
to excited agreement. collaboration. it option the out-licensing exclusive license development any of generated very first part the this our is as as has partnership We're about Astellas candidate
and antibody discovery Biopharma a immuno-oncology its Cells is in leader Twist validation optimization with T Donor and Universal platform. it's CAR Astellas and the a for fantastic
milestones term received payment, and licensing Another an clinical Twist the on royalties an as Twist each product developed as upside to exercise nice the of agreement build upfront agreement. and product an to base of and receive for payment later-stage option success-based and we're we receive entitled we sales opportunities. will upon under additional a pursue larger This is initial for serve on the Twist
parallel. we advance multiple And through to we're optimization regard because to the macro at and the have continues discovery. large move capability multiple approaches see interest biopharma We part, we overall a partners. list due And in for engagement solid going new targeting with projects of project to partners not are differentiated team antibody both management that Our to offerings Biopharma with we our believe the forward data and number to In potential more see on risk environment We growing and discovery biopharma not restrictive space, the out away. in seamless those We funding resonate. projects accounts in path. On customers, few. a diversified electronic antibodies but and find to do push out continue bid current controls our our continue some environment integrated and X micron fully pitch. debug dependent with of a across is just we programs storage
enable our we synthesize be a expand Initially, run. we synthesis offered data is will to as of will writing, which a market, shared up introduce solution. we are solution data storing storage commercial with To to access able to we X early the a fastest with pricing gigabyte single writing achieve approach customers. in for storage objective to time as Our this launch. service and Archive into a Once the retrieving as service Century start will will
scale over be data And we an and The and will today. on that data report in premises iPhone the And we a new to be estimates from hyperscaler is highest enterprise paper matures detailing the be X storage the Earlier white that to shared an be DNA about enterprise accessible As data archive located XXXX. will a be can is of massive environment available minimal in dramatic need highlights expect at terabyte deployed zettabyte fits sites. power a not this data that coming the the billion new increasing consumption. from could which to automation to be all a accessible technology address terabytes. This at reminder as targeted large report storage XX solution The market week, storage introduce market further be XX% able will demand data realized, capacity as can demand with our center technology upcoming technologies as growing parallel has ever. storage that opportunity these to unmet features features served perspective. by current evolution delay the NIE. In zettabyte the educational of meet research. from for technology. for demand This DNA as also technician need which The Association today. into for affiliate will key parallel of group the about technology development data the build is a alliance as to continue And universally this now executive whole. of review not means of Industry from XX% became we to interoperative density as do data that an intend down key is an our data a with storage industry organization durability, alliance interviews a storage they market industry storage data in to Jim ecosystem I'd DNA that well make data of building indicated drive positioned Storage And storage. it the the indefinite to known development, required data important like new storage storage with an DNA significant media turn a Networking to a strides that our stand are to reproducibility DNA financials. for and
